Vanguard Capital Management
COCP icon

Vanguard Capital Management’s Cocrystal Pharma COCP Stock Holding History

Vanguard Capital Management’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$376K Buy
358,228
+118,257
+49% +$146K ﹤0.01% 3754
2026
Q1 		$242K Buy
+239,971
New +$248K ﹤0.01% 3776

Other funds holding COCP

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management's COCP Position: Q2 2026 in Review

Vanguard Capital Management increased its Cocrystal Pharma (COCP) stake by 49% in Q2 2026, buying an estimated $146K and bringing the position to 358,228 shares worth $376K. The position accounts for ﹤0.01% of the portfolio, ranked #3754.

Vanguard Capital Management first reported a position in COCP in Q1 2026 and has held it in 2 quarters since. 27 funds tracked by Wall St. Rank hold COCP as of Q2 2026.

  • Vanguard Capital Management held 358,228 shares of Cocrystal Pharma worth $376K as of Q2 2026.
  • Vanguard Capital Management bought 118,257 Cocrystal Pharma shares in Q2 2026, an estimated $146K.
  • Cocrystal Pharma made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3754 holding.
  • Vanguard Capital Management first reported a position in Cocrystal Pharma in Q1 2026 and has held it in 2 quarters since.
  • 27 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.